MeMed Stock

MeMed Diagnostics is a personalized diagnostics company, focused on preventing antibiotics misuse.

Sign up today and learn more about MeMed Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About MeMed Stock

MeMed Diagnostics is a personalized diagnostics company founded in 2009. They are here to improve patient care, empower physicians, and lower health-care costs through rapid and actionable diagnostics for infectious diseases. Their main focus is preventing antibiotics misuse. Antibiotics are the most prescribed class of drugs worldwide with a global market of 25-30 billion $US. Up to 70% of antibiotics are estimated to be prescribed inappropriately, making them the most misused drug class in the world. Antibiotics misuse leads to ineffective treatment, emergence of resistant strains of bacteria, and is estimated to cost healthcare systems worldwide tens of billions of dollars annually. Their platform, the ImmunoDx™, leverages the world’s most accurate diagnostic system for differentiating bacteria from viruses, crafted by nature, the body’s immune system. ImmunoDx™ combines proprietary biomarkers, algorithms, and clinical know-how to identify the source of infection (virus vs bacteria, bacterial spectrum), by decoding the immune system`s differential response to different pathogens. This unique approach enables ImmunoDx™ to address some of the major challenges facing currently available diagnostics for infectious diseases.

Funding History

December 2015$2.9M
February 2018$4.1M
September 2018$70.0M
November 2019$2.5M
January 2022$93.0M



Oren Zarchin

VP of Human Resources

Hila Hershkovitz

VP Finance

Kfir Emmer


Lyon Wong


Idan Danenberg


Kent Ho

Chief Business Development Officer

Frederic Sweeney

VP Commercial Strategic Markets

Adee Mor

VP Commercial and Corporate Development

Ofer Halbreich

Co-founder and CEO

Eran Eden

Co-founder, CTO, Chairman

Kfir Oved

VP of Scientific Affairs

Tanya Gottlieb

Director of Regulatory Affairs and Quality Assurance

Efrat Hartog-David


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: